GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Enorama Pharma ERMA.ST · SEK

Health Care · Nasdaq Stockholm · 🇸🇪 Sweden

Compare

0.76

-4.75%

Close of 9 Nov 2026, in SEK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Enorama Pharma

Its shares trade on Nasdaq Stockholm under the ticker ERMA.ST. It has been listed since 10 June 2016. In the fiscal year to 31 December 2025, it reported revenue of SEK 2.7m and a net loss of SEK 75.1m. At that date it held total assets of SEK 8.3m and shareholders' equity of −SEK 23.5m.

Enorama Pharma AB engages in the research, development and manufacture of pharmaceutical drug delivery system. The company is headquartered in Malmo, Skane. The company went IPO on 2016-06-10. The firm is mainly focused on the development of medical chewing gum that contains drugs. The firm's product Nicotine gum is a chewing gum contained drugs that help to overcome nicotine addiction. In addition, the medical chewing gum applications include pain management, allergy, cough and cold, among others. The firm distributes its products in Europe through pharmacy chains and grocery stores.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
10 Jun 2016
Website
enorama.se ↗

Leadership

Pay as last reported

  • Mr. Bengt JonssonChairman of the Board, since 2019
  • Mr. Daniel SchroderChief Executive Officer
  • Mr. Jonas BrislandChief Financial Officer
  • Mr. Claes EliassonActing Chief Financial Officer
  • Mr. Fredrik OlssonDirector
  • Mr. Tanu TandanDirector
  • Mr. Mikael AbomIndependent Director
  • Ms. Katarina StenborgInvestor Relations Contact Officer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Malmö, Skåne, Sweden
  • Focus on pharmaceutical drug delivery systems including medical chewing gum
  • Products distributed in Europe through pharmacy chains and grocery stores

Weaknesses

  • Limited product range beyond nicotine gum and related applications
  • Dependence on European distribution channels for product sales
  • No mention of global market presence or international expansion

Opportunities

  • Expansion of medical chewing gum applications to new therapeutic areas
  • Potential for international market entry beyond Europe
  • Growth in demand for non-invasive drug delivery systems

Threats

  • Competition from traditional pharmaceutical delivery methods
  • Regulatory challenges in drug delivery system approvals
  • Market saturation in nicotine addiction treatment segment

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.